BI-1569912
- Generic Name
- BI-1569912
A Study to Test Different Doses of BI 1569912 in People With Depression
- Conditions
- Depressive Disorder, Major
- Interventions
- Drug: Placebo matching BI 1569912
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 224
- Registration Number
- NCT06558344
- Locations
- 🇺🇸
Surburban Research Associates, Inc., Media, Pennsylvania, United States
🇺🇸Clinical Innovations, Inc, Bellflower, California, United States
🇺🇸ASCLEPES Research Centers, P.C. dba Alliance Research, Long Beach, California, United States
A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT06367153
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT06280235
- Locations
- 🇨🇳
Hebei Mental Health Center, Baoding, China
🇯🇵Kaku Mental Clinic, Fukuoka-shi, Japan
🇺🇸Excell Research Inc., Oceanside, California, United States
A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 83
- Registration Number
- NCT04978506
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT04958252
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 59
- Registration Number
- NCT04937829
- Locations
- 🇺🇸
Research Centers of America, Oakland Park, Florida, United States
🇺🇸Collaborative Neuroscience Research, LLC, Torrance, California, United States
🇺🇸Optimus U Corporation, Miami, Florida, United States
A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 68
- Registration Number
- NCT04445090
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.